DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
3 Reasons Growth Investors Will Love DexCom (DXCM)
by Zacks Equity Research
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
What Makes DexCom (DXCM) a New Buy Stock
by Zacks Equity Research
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ensign Group (ENSG) Q3 Earnings Beat on Occupancy, Stock Up 2.4%
by Zacks Equity Research
Ensign Group's (ENSG) third-quarter results benefit on solid segmental contribution and occupancy strength. Management currently expects adjusted EPS to be within $4.73-$4.79 for 2023.
DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 47.06% and 4.02%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how WST, DXCM, MMSI and ITGR are placed ahead of their earnings releases.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.
Will Patient Volumes Aid Community Health's (CYH) Q3 Earnings?
by Zacks Equity Research
Community Health's (CYH) third-quarter results are likely to benefit from improved payer mix and growing surgery volumes, partly offset by a decline in patient days.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.
Can DexCom (DXCM) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why the Market Dipped But DexCom (DXCM) Gained Today
by Zacks Equity Research
The latest trading day saw DexCom (DXCM) settling at $80.49, representing a +1.95% change from its previous close.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $83.09, moving -0.16% from the previous trading session.
Here's Why DexCom (DXCM) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom (DXCM) to Launch Latest CGM System G7 in Canada
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $94.55, marking a +1.34% move from the previous day.
Buy this Tech Stock on the Dip in October for 50% Upside?
by Benjamin Rains
DXCM stock is currently down over 40% from its 2021 highs and trading 51% below its average Zacks price target even though it stands out in the connected health world that's likely to become standard medical practice.
Dynatronics Corporation (DYNT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -85.29% and 5.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring
by Zacks Equity Research
DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.
Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $94.16 in the latest trading session, marking a -1.19% move from the prior day.
Should Vanguard Mid-Cap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO